Effect of ursodeoxycholic acid on HCV replication in subtyped chronic hepatitis C

A trial of high-dose ursodeoxycholic acid therapy in a liver transplant recipient

“…In our patient, recently determined serum total bile acid and UDCA concentrations have been as high as 115 pM and 88 pM (77 % of total bile acids), respectively. Recently, Mohler et al [7] also reported that UDCA (500 mg/day) had no impact on titers of HCV RNA, while a 3month UDCA treatment significantly improved transaminases and cholestatic enzymes in chronic HCV patients. Thus, the major improvement in liver enzymes in patients with chronic HCV is not induced by a significant change in HCV replication.…”